Cytotronics Launches With $9.25 Million In Seed Funding To Revolutionize Drug Discovery And Phenotypic Screening

CytoTronics, a biotechnology company building a next-generation complementary metal-oxide-semiconductor (CMOS)-powered drug discovery platform, today announced it has raised $9.25M in initial seed funding, led by Anzu Partners with participation from Milad Alucozai (BoxOne Ventures) and institutional investors. CytoTronics will use this seed funding to advance its breakthrough platform that utilizes computer chip technology to conduct a suite of electrical and electrochemical cell-based assays.